Skip to content

Author

J. Tardif

We have 6 of 104 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Clearance of p16‐positive cardiac cells improves age‐related cardiac remodeling in mice

Significant attenuation of aging‐associated increases in left ventricular mass to diameter at end‐diastole (LVDd) and anterior wall thickness at end diastole (LVAWTd) in Aged‐AP mice versus Aged‐Vehicle was revealed.

Mozhdeh Mehdizadeh, Martin Mackasey, Kimia Gharagozloo et al. · 0 citations
Open access Sep 2026

CYP2D6 Metabolizer Status and Mortality in Metoprolol Users

Numerous pharmacogenomic (PGx) associations of pharmacokinetics and pharmacodynamics of commonly prescribed medications have been reported. Yet, the evidence supporting their association on survival remains underexamined. We sought to investigate the CYP2D6‐metoprolol association and determine whether the established v...

S. de Denus, Essaïd Oussaïd, Maxime Meloche et al. · 0 citations
Open access Sep 2026

Cross-sectional evaluation of anthropometric measures vs MRI-measured visceral and hepatic fat in a Canadian cohort

Abstract Context Accurate assessment of excess body fat and its cardiometabolic risk is essential in clinical and epidemiologic research. Body-mass index (BMI), although widely used, does not capture visceral or ectopic fat. Objective To evaluate how anthropometric measures—BMI, percent body fat, waist circumference (W...

B. Al-Khazraji, R. D. de Souza, D. Desai et al. · 0 citations
Open access Sep 2026

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.

Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.

M. Szarek, Deepak L. Bhatt, Michael Miller et al. · 0 citations
Open access Aug 2026

Lipid Profiles in Liver Steatosis and Liver Fibrosis in Patients with Type 2 Diabetes and Coronary Artery Disease

Patients with T2DM, cardiovascular disease, and blood-based indices suggesting liver steatosis or fibrosis differed significantly with respect to the lipid profile, and an elevated HSI score, suggesting steatosis, was associated with dyslipidemia, and an elevated NFS score, suggesting fibrosis, was not.

Laura A. M. Konings, Weiwei Xu, Vivian D. de Jong et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.